Wheeler Bio, Inc. Company Profile

Background

Founded in 2020, Wheeler Bio, Inc. is a contract development and manufacturing organization (CDMO) headquartered in Oklahoma City, Oklahoma. The company specializes in accelerating the translation of therapeutic innovations into clinical applications, focusing primarily on antibody-based therapies. Wheeler Bio's mission is to streamline the discovery-to-IND (Investigational New Drug) process, providing emerging biopharmaceutical companies with a faster and more predictable path to clinical trials. By integrating discovery capabilities with open-source biomanufacturing processes, Wheeler Bio aims to democratize access to rapid, high-quality biomanufacturing solutions.

Key Strategic Focus

Wheeler Bio's strategic focus centers on its proprietary Portable CMC™ platform, designed to bridge the gap between drug discovery and clinical manufacturing. This platform offers a comprehensive suite of services, including manufacturability assessments, stable pool and clone development, process and analytical method development, process demonstration, and technology transfer into CGMP (Current Good Manufacturing Practice) production. By integrating these services, Wheeler Bio enhances the efficiency and predictability of the translational process, reducing technical, regulatory, and business risks for its clients.

Financials and Funding

Since its inception, Wheeler Bio has successfully secured significant funding to support its growth and expansion:

Seed Round (January 2022): Raised $14 million, co-led by Echo Investment Capital and Alloy Therapeutics, with participation from Floating Point and Presbyterian Health Foundation.

Series A Round (April 2023): Closed a $31 million round co-led by Charles River Laboratories and Echo, with contributions from ATUM, Floating Point Advisors, Pine Ridge Ventures, Plains Venture Partners, Seagull Capital, and Alloy Therapeutics.

Series A-1 Round (March 2025): Secured an oversubscribed $35 million round led by Alloy Therapeutics and Echo Investment Capital, with participation from Mitsubishi Corporation (Americas), Germin8 Ventures, and Russell Westbrook Enterprises.

These funds have been allocated towards expanding Wheeler Bio's team, enhancing the Portable CMC™ platform, and establishing state-of-the-art CGMP manufacturing facilities.

Technological Platform and Innovation

Wheeler Bio's innovation is anchored in its Portable CMC™ platform, which serves as an open-source "CMC middleware" to efficiently connect discovery with clinical manufacturing. This platform includes:

Manufacturability Assessments: Evaluating the feasibility of production processes for therapeutic candidates.

Stable Pool and Clone Development: Creating robust cell lines for consistent therapeutic production.

Process and Analytical Method Development: Designing and optimizing manufacturing processes and analytical methods.

Process Demonstration and Technology Transfer: Validating processes and transferring them into CGMP production environments.

The platform integrates advanced technologies such as the Leap-In Transposase® system from ATUM, Solentim® instruments, Ambr® Microbioreactors, DynaDrive Single-Use Bioreactors, the Synthace Experiment Platform, and DataHowLab, enhancing the efficiency and predictability of the translational process.

Leadership Team

Wheeler Bio's leadership comprises experienced professionals with extensive backgrounds in biopharmaceutical development and manufacturing:

Patrick Lucy: President and Chief Executive Officer.

Jesse McCool, Ph.D.: Co-Founder and Chief Executive Officer.

Matt Hamilton: Chief Financial Officer.

Brian Berquist: Chief Development Officer and Senior Vice President.

Stewart McNaull: Chief Business Officer.

Yuk Chun Chiu: Chief Manufacturing Officer.

Marc Helouin: Chief Quality and Regulatory Officer.

These leaders bring a wealth of experience from various sectors within the biopharmaceutical industry, driving Wheeler Bio's mission to accelerate therapeutic innovation.

Leadership Changes

In August 2023, Wheeler Bio appointed Marc Helouin as Chief Quality and Regulatory Officer. With over 25 years of experience in biopharma, including roles in quality assurance and regulatory affairs, Helouin's addition strengthens the company's commitment to quality and compliance.

Competitor Profile

Market Insights and Dynamics

The biopharmaceutical CDMO market is experiencing significant growth, driven by increasing demand for biologics and the need for specialized manufacturing capabilities. Companies like Wheeler Bio are capitalizing on this trend by offering integrated services that streamline the path from discovery to clinical trials.

Competitor Analysis

Key competitors in the biopharmaceutical CDMO space include:

Lonza Group: A global leader in biopharmaceutical manufacturing, offering a wide range of services from development to commercial production.

Abcam: Specializes in the production and distribution of research-grade antibodies and related products.

Bio-Techne: Provides tools and reagents for the research and clinical diagnostic markets.

Sartorius AG: Offers laboratory and process technologies and equipment.

Thermo Fisher Scientific: A global provider of scientific instrumentation, reagents, and consumables.

Wheeler Bio differentiates itself through its Portable CMC™ platform and focus on accelerating the discovery-to-IND process for emerging biopharma companies.

Strategic Collaborations and Partnerships

Wheeler Bio has established significant partnerships to enhance its service offerings:

Charles River Laboratories: In February 2024, Wheeler Bio entered into a strategic agreement with Charles River to offer the Portable CMC™ platform to Charles River's discovery clients, facilitating a swift transition from pre-clinical stages to human clinical trials.

Alloy Therapeutics: A partnership aimed at integrating discovery capabilities with Wheeler Bio's biomanufacturing processes, providing a seamless path to IND clinical manufacturing.

These collaborations strengthen Wheeler Bio's market position and expand its capabilities in the biopharmaceutical development landscape.

Operational Insights

Wheeler Bio's operational strategy includes a hub-and-spoke model, with its central CGMP facility located in Oklahoma City and satellite preclinical material supply labs in biotech hubs. This structure enhances accessibility, affordability, and agility compared to larger CDMO service providers. The company's state-of-the-art 35,000 square foot CGMP facility features two single-use drug substance lines (50L and 500L scale), warehousing, cold chain storage, and quality control testing labs operated by Charles River's RightSource℠.

Strategic Opportunities and Future Directions

With the recent $35 million Series A-1 funding, Wheeler Bio plans to expand its capabilities, including the development of a 52,000 square foot large-scale biologics manufacturing facility adjacent to a biomanufacturing workforce training center in the Oklahoma City Innovation District. This expansion aims to meet the growing demand for platforms that accelerate the transition from bench to bedside, positioning Wheeler Bio as a key player in the biopharmaceutical CDMO market.